A 52-week, open-label, observational study evaluating tolerability, efficacy and physicians satisfaction of rivastigmine oral solution in Alzheimer's disease in Taiwan
{{output}}
Background: There is limited data on the use of rivastigmine oral solution in patients with Alzheimer's disease (AD). Objective: To evaluate t... ...
